Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech's New Deal Maker

This article was originally published in Start Up

Executive Summary

In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.

You may also be interested in...



Sabry Takes BD Reins at Roche's gRED

The recent appointment of James Sabry, MD, PhD, as Genentech's new head of business development is Roche's latest attempt to retain the spirit of the once-independent biotech icon.

Pharma and Academia: Finding New Ways to Join Hands for Mutual Benefit

As Big Pharmas seek to hedge their development risk and look for more externally sourced programs, partnerships with academic institutions are one of the many ingredients in the R&D secret sauce. Such deals aren't the academic-industry tie-ups of yore-where Big Pharma sought small money partnerships without giving a lot back to their academic partners. Business development execs view them as yet another way to access critically important innovation.

Business Development at Roche and Genentech: An Interview with Joe McCracken and Dan Zabrowski

What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel